Manuscripts
Showing 1530 manuscripts.
Decreased growth among antiretroviral drug and HIV-exposed uninfected versus unexposed children in Malawi and Uganda
Citation
Jim Aizire, Alla Sikorskii, Lillian Wambuzi Ogwang, Rachel Kawalazira, Alex Mutebe, Itziar Familiar-Lopez, MacPherson Mallewa, Taha Taha, Michael J Boivin, Mary Glenn Fowler, PROMISE NEURODEV Study Team. Decreased growth among antiretroviral drug and HIV-exposed uninfected versus unexposed children in Malawi and Uganda. AIDS. 2020. 34: 215-225. PMID: 31634154Year
2020
Journal
AIDS
Study
1077BF
Comparison of guidelines for HIV viral load monitoring among pregnant and breastfeeding women in sub-Saharan Africa
Citation
Maia Lesosky, Janet M Raboud, Tracy Glass, Sean S Brummel, Andrea L Ciarnello, Judith S Currier, Shaffiq Essajee, Diane V Havlir, Catherine A Koss, Anthony Ogwu, Roger L Shapiro, Elaine J Abrams, Landon Myer. Comparison of guidelines for HIV viral load monitoring among pregnant and breastfeeding women in sub-Saharan Africa. AIDS. 2020. 34: 311-315. PMID: 31634186Year
2020
Journal
AIDS
Study
1077BF, 1077FF, 1077HS
The impact of short term Antiretroviral Therapy (ART) interruptions on longer term maternal health outcomes-A randomized clinical trial
Citation
Patience Atuhaire, Sean S Brummel, Blandina Theophil Mmbaga, Konstantia Angelidou, Lee Fairlie, Avy Violari, Gerhard Theron, Cornelius Mukuzunga, Sajeeda Mawlana, Mwangelwa Mubiana-Mbewe, Megeshinee Naidoo, Bonus Makanani, Patricia Mandima, Teacler Nematadzira, Nishi Suryavanshi, Tapiwa Mbengeranwa, Amy Lofits, Michael Basar, Katie McCarthy, Judith S Currier, Mary Glenn Fowler, 1077BF/1077FF PROMISE Team. The impact of short term Antiretroviral Therapy (ART) interruptions on longer term maternal health outcomes-A randomized clinical trial. PLoS One. 2020. 15: e0228003. PMID: 31999753Year
2020
Journal
PLoS One
Study
1077BF, 1077FF
Willingness to Take Multidrug-Resistant Tuberculosis (MDR-TB) Preventive Therapy among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multi-Site Cross-Sectional Study
Citation
N Suryavanshi, M Murrill, A Gupta, M Hughes, A Hesseling, S Kim, L Naini, L Jones, B Smith, N Gupte, R Dawson, V Mave, S Meshram, A Mendoza-Ticona, J Sanchez, N Kumarasamy, K Comins, F Conradie, J Shenje, S Nerette Fontain, A Garcia-Prats, A Asmelash, S Nedsuwan, L Mohapi, U Lalloo, ACG Ferreira, E Okeyo, G Churchyard, NS Shah. Willingness to Take Multidrug-Resistant Tuberculosis (MDR-TB) Preventive Therapy among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multi-Site Cross-Sectional Study. Clinical Infectious Diseases. 2020. 70: 436-445. PMID: 30919881Year
2020
Journal
Clinical Infectious Diseases
Study
IMPAACT 2003/ACTG 5300
Feasibility of Identifying Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease
Citation
A Gupta, S Swindells, S Kim, MD Hughes, L Naini, X Wu, R Dawson, V Mave, J Sanchez, A Mendoza, P Gonzales, N Kumarasamy, K Comins, F Conradie, J Shenje, SN Fontain, A Garcia-Prats, A Asmelash, S Nedsuwan, L Mohapi, UG Lalloo, ACG Ferreira, C Mugah, M Harrington, L Jones, S Cox, B Smith, NS Shah, AC Hesseling, G Churchyard, ATCG 5300/IMPAACT I2003 PHOENIx Feasibility Study Team. Feasibility of Identifying Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease. Clinical Infectious Diseases. 2020. 70: 425-435. PMID: 30942853Year
2020
Journal
Clinical Infectious Diseases
Study
IMPAACT 2003/ACTG 5300
Predictors of Viremia in Postpartum Women on Antiretroviral Therapy
Citation
Risa M Hoffman, Meredith G Warshaw, K Rivet Amico, Jose Pilotto, Gaerolwe Masheto, Jullapong Achalapong, Elizabeth Machado, Kulkanya Chokephaibulkit, Geraldo Duarte, Esau Joao, Kathleen K Graham, Katherine M Knapp, Alice M Stek, Gwendolyn B Scott, Anne Coletti, Amy J Loftis, Nahida Chakhtoura, Judith S Currier, PROMISE 1077HS Team. Predictors of Viremia in Postpartum Women on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes. 2020. 83: 72-80. PMID: 31651545Year
2020
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
1077HS
Extended Prophylaxis With Nevirapine Does Not Affect Growth in HIV-Exposed Infants.
Citation
C Onyango-Makumbi, AH Owora, RS Mwiru, A Mwatha, AM Young, D Moodley, HM Coovadia, L Staranix-Chibanda, K Manji, Y Maldonado, P Richardson, P Andrew, K George, W Fawzi, MG Fowler. Extended Prophylaxis With Nevirapine Does Not Affect Growth in HIV-Exposed Infants.. Journal of Acquired Immune Deficiency Syndromes. 2019. 82: 377-385. PMID: 31567725Year
2019
Journal
Journal of Acquired Immune Deficiency Syndromes
Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110
Citation
Diana F Clarke, Mark Mirochnick, Edward P Acosta, Edmund Capparelli, Anne Chain, Hedy Teppler, Betsy Smith, Jos Lommerse, International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1110 Study Team. Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110. Journal of Acquired Immune Deficiency Syndromes. 2019. 82: 392-398. PMID: 31658182Year
2019
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
P1110
Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis
Citation
Kartik Kailas Venkatesh, Mona Farhad, Terry Fenton, Dhayendre Moodley, Shilpa Naik, Clemensia Nakabiito, Lee Fairlie, Mary Glenn Fowler, Jeffrey S A Stringer, Benjamin H Chi. Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis. AIDS. 2019. 33: 2403-2413. PMID: 31764105Year
2019
Journal
AIDS
Study
1077BF, 1077FF
Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis
Citation
T Meyers, P Samson, EP Acosta, J Moye, E Townley, S Bradford, L Marillo, K Denson, L Hovind, T Sise, H Teppler, SR Mathiba, A Hesseling, MF Cotton, P Krogstad, IMPAACT P1101 Team. Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis. AIDS. 2019. 15: 2197-2203. PMID: 31689263Year
2019
Journal
AIDS